Skip to main content
Podcasts

Discussing Effectiveness, Persistence Rates for Atopic Dermatitis Therapy


August 13, 2020

logoJonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues sought to better describe adult patients with atopic dermatitis initiating dupilumab treatment in a clinical practice setting, with regard to socio-demographic characteristics, comorbidity, treatment patterns, and persistence.

References:

  1. Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis (AD). Poster presented at: The Society for Investigative Dermatology (SID) 77th Annual Meeting; May 8–11, 2019; Chicago, IL.
  2. Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis (AD). Oral presentation at: The Society for Investigative Dermatology (SID) 77th Annual Meeting; May 8–11, 2019; Chicago, IL.

Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
6 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top